Angiodynamics (ANGO) Change in Accured Expenses (2010 - 2026)

Angiodynamics (ANGO) has 17 years of Change in Accured Expenses data on file, last reported at $7.7 million in Q2 2026.

• Quarterly Change in Accured Expenses rose 197.14% year-over-year to $7.7 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$5.8 million (up 63.26% YoY) and the FY2026 annual result came in at -$5.8 million, up 63.26% from the prior year.
• Change in Accured Expenses rose to $7.7 million in Q2 2026, from -$6.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $17.7 million in Q1 2024 to a low of -$16.5 million in Q3 2023.
• A 5-year average of $910333.3 and a median of $2.9 million in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 446.88% — and 2024, when it soared 515.14%.
• Tracing ANGO's Change in Accured Expenses over 5 years: stood at $6.1 million in 2022, then surged by 153.34% to $15.6 million in 2023, then sank by 51.97% to $7.5 million in 2024, then tumbled by 57.48% to $3.2 million in 2025, then surged by 142.01% to $7.7 million in 2026.
• The last three Change in Accured Expenses figures came in at $7.7 million (Q2 2026), -$6.0 million (Q1 2026), and $3.2 million (Q4 2025), per Business Quant data.